1) RGN259 is enrolling for a Phase II trial this quarter and the trial will take place through 2011, according to a recent news report.
2) Rexolvyx has a new partner, Celtic Therapeutics, who have an option to acquire and license RX-10045, according to a press release.
2) Rexolvyx has a new partner, Celtic Therapeutics, who have an option to acquire and license RX-10045, according to a press release.